Royalty Report: Delivery, Drugs, Pharmaceuticals – Collection: 2759


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 18


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 18

Primary Industries

  • Delivery
  • Drugs
  • Pharmaceuticals
  • Therapeutic
  • Medical
  • Tobacco
  • Cannabis
  • Device
  • Dental
  • Supply
  • Hormones

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2759

License Grant
The Licensee, a spin-off of the Licensor purchased assets of iontophoresis drug delivery products and related research and development program, as well as related patents, patent applications and other intellectual property.
License Property
Iontophoresis is an active transdermal drug delivery technology.

The Licensee has developed and produced the first FDA – approved electronically controlled transdermal drug delivery system that transports drugs through the skin comfortably, without needles.  Our active transdermal drug delivery technology is based on a process known as electrotransport, or more specifically iontophoresis, a process that transports drugs, including peptides, through the skin by applying a low-level electrical current. Our active patch patented technology works by applying a charge to the drug-holding reservoir of the patch. This process differs significantly from passive transdermal drug delivery which relies on the slow, steady diffusion of drugs through the skin. A significantly greater number of drugs can be delivered through active transdermal delivery than is possible with passive transdermal delivery. Based on our analysis thus far, we estimate that there are currently over 220 FDA-approved drugs that may be delivered through our active transdermal delivery platform.

Field of Use
The Licensee is required to pay the Licensor a royalty in respect of sales of each iontophoresis product stemming from intellectual property received from the Licensor.

IPSCIO Record ID: 570

License Grant
The Company shall sell, assign, transfer, convey and deliver to Purchaser, and Purchaser shall purchase, acquire and accept from the Company, all of the Company's right, title and interest in and to those certain assets  (the 'Intellectual Property').
License Property
The Company has developed and owns the certain Intellectual Property which it refers to as the 'U-Strip' Technology.

The technology refers to certain intellectual property encompassing a new type of non-invasive drug delivery system more commonly known as a transdermal patch.

Passive drug delivery patches have applications including smoking cessation (nicotine), birth control and hormone replacement therapy (estradiol), and angina (nitroglycerine). By contrast, active transdermal drug delivery systems allow certain drugs to be delivered through the skin many times faster than passive transdermal patches.

IPSCIO Record ID: 273586

License Grant
Licensor grants an exclusive license of the Licensor KnowHow to package, use, offer for sale and sell the Product in the Territory.
License Property
Licensor has rights to technology in relation to the development and production of drug specific dosage forms.

Licensor is knowledgeable in the development of drug specific oral and transdermal dosage forms and has developed a unique range of delivery systems designed to provide newer and better formulations of medicaments.

Field of Use
The Licensee entered into a licensing agreement to market a clonidine transdermal patch, a generic version of Catapres TTS®.
Catapres-TTS (clonidine) transdermal therapeutic system is a square, tan adhesive patch containing an active blood-pressure-lowering medication. It is designed to deliver the drug into the body through the skin smoothly and consistently for one full week.

IPSCIO Record ID: 256229

License Grant
Licensee desires to acquire certain assets and rights pertaining to Eladur® and obtain a license to Licensor's proprietary TRANSDUR® transdermal delivery technology and other intellectual property to develop and commercialize Eladur®, and Licensor desires to transfer such assets and grant such a license to Licensee.

For the  License to Product, Licensor grants an exclusive license under the Licensed Technology, other than specific third party patents, solely to make, have made, use, import, sell, offer for sale and otherwise develop and Commercialize Products in the Field in the Territory, and, as permitted, an exclusive sublicense under Licensors license to Licensee Patents solely to make, have made, use, import, sell, offer for sale and otherwise Develop and Commercialize Products that contain bupivacaine, and no other Bupivacaine compound as the sole active ingredient, in the Field in the Territory.

Licensor grants to a limited right to use the trademark 'TRANSDUR®' solely in connection with the sale and marketing of Products in the Field within the Territory in accordance with this Agreement.

License Property
Licensor owns and controls rights in and to its product known as Eladur®, which is a transdermal bupivacaine patch based on Licensors proprietary TRANSDUR® transdermal delivery technology.

Bupivacaine shall mean bupivacaine, or any enantiomer, polymorph, salt form, racemate, isomer, diastereomer, tautomer, solvate, hydrate, or ester of bupivacaine.

Product shall mean any transdermal patch containing Bupivacaine as the sole active ingredient, including Eladur® as further described in IND No. 75,436.

TRANSDUR® Technology is defined as pharmaceutical transdermal patch drug delivery systems for use with a range of pharmaceutical preparations for sustained release of medication into the body, wherein the transdermal patch comprises a backing layer; a pressure-sensitive adhesive layer; and a release liner, wherein the pressure-sensitive adhesive layer comprises active agent, polyisobutylene, and plasticizer.

ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.
Bupivacaine is an anesthetic (numbing medicine) that blocks nerve impulses in your body. Bupivacaine is used as a local (in only one area) anesthetic. Bupivacaine is given as an epidural injection into the spinal column to produce numbness during labor, surgery, or certain medical procedures.

Field of Use
The agreement is for the rights to develop and commercialize ELADUR®, Licensor's investigational transdermal bupivacaine patch for the treatment of pain associated with post-herpetic neuralgia (PHN).

Postherpetic neuralgia s the most common complication of shingles. The condition affects nerve fibers and skin, causing burning pain that lasts long after the rash and blisters of shingles disappear. The chickenpox (herpes zoster) virus causes shingles.  Postherpetic neuralgia is a painful condition that affects your nerves and skin. It is a complication of herpes zoster, commonly called shingles. When the pain caused by shingles doesn't go away after the rash and blisters clear up, the condition is called postherpetic neuralgia.

IPSCIO Record ID: 233493

License Grant
The Licensee of Bermuda wishes the Licensor of Bermuda to develop the System as a method of drug delivery incorporating the compound for the Field.

The Licensor of Bermuda grants to the Licensee of Bermuda an exclusive license to the Licensors Background Technology and Licensors Improvements to package, import, use, offer for sale and sell and otherwise distribute the Product for the Field in the Territory.

Licensor also grants a non-exclusive license in the Territory to use the Licensors Trademark solely for the purposes of exercising its rights and performing its obligations under this Agreement.

License Property
The patents and technology are for Medipad, and, an Improved Method of Packaging a Drug Delivery Kit .

The Compound shall mean any formulations of Desferoxamine and any of its analogues, isomers or derivatives.

The System shall mean the ambulatory subcutaneous infusion drug delivery system for direct attachment to the body of a patient having a flexible diaphragm drug reservoir, which is capable of delivering factory pre-programmed continuous amounts of drug upon activation as disclosed and described in the Licensors patents.

Deferoxamine (DFOA) is a medication that binds iron and aluminium. It is specifically used in iron overdose, hemochromatosis either due to multiple blood transfusions or an underlying genetic condition, and aluminium toxicity in people on dialysis. It is used by injection into a muscle, vein, or under the skin.

Field of Use
The field shall mean the treatment of any iron overloading disorder by subcutaneously delivering the Compound using the System.

IPSCIO Record ID: 28610

License Grant
The Licensor entered into a License Agreement with the Licensee, granting rights to the Accudel delivery technology to be used for anti-cellulite formulations.
License Property
The Licensor is a specialty pharmaceutical company focused on the commercial development of compounded drug formulations. The Licensor expects to use its proprietary Accudelâ„¢ drug delivery technologies, proprietary drug formulations, and its exclusive relationship with Professional Compounding Centers of America, Inc., to identify pharmaceutical development opportunities where there are significant unmet medical needs.

The Accudelâ„¢ Topical Drug Delivery System is a patented formulation which provides transdermal delivery of high percentage formulations of drugs, both small and large molecules, by a route that avoids first pass metabolism and significant systemic exposure. Accudelâ„¢ contains penetration enhancers which function synergistically to provide for rapid, but controllable transport of an active medication from the Accudel cream onto the skin and into the underlying soft tissue.

Accudelâ„¢ is biodegradable and has low toxicity.  Accudel is made of non-immunogenic components, is thermodynamically stable and is quickly absorbed, as well as being aesthetically pleasing to many.

IPSCIO Record ID: 204556

License Grant
Licensor grants to Licensee exclusive Worldwide rights to BiPhasix Transdermal Drug Delivery Technology for the delivery and commercialization of Cannabinoids, Cannabidiol (CBD), and Tetrahydrocannabinol (THC) based products.
License Property
The term “Product” shall mean any pharmaceutical product, development candidate for human or animal use arising out of the collaboration based on the BiPhasix CBD Intellectual Property Rights.

Biphasixâ„¢ is a needle-free, noninvasive, particulate drug delivery system suitable for intra- and transdermal delivery of drugs.

BiPhasixâ„¢ can entrap and transport pharmaceutical products through the skin to achieve therapeutic benefit in a wide range of indications. Studies have shown that BiPhasixâ„¢ can significantly enhance the bioavailability of many drugs, leading to improved clinical outcomes. In addition, this proprietary technology can serve as an alternative dosage form to injectables by providing less invasive routes of administration such as dermal, transdermal, nasal, vaginal, ocular, and rectal.

Field of Use
The rights are to BiPhasixâ„¢ transdermal drug delivery technology for the development and commercialization of Cannabinoids, Cannabidiol (CBD) and Tetrahydrocannabinol (THC) products.

The Company will use for the delivery and commercialization of cannabinoid, cannabidiol and tetrahydrocannabinol-based products.

IPSCIO Record ID: 372446

License Grant
Having been made aware of the rights of Licensor, an individual of France with regard to the invention, the Licensee of the Netherlands now intends to recognize these rights in order to guarantee untroubled use of the patent.

The Licensee acknowledges Licensors role as the co-inventor of the invention and therefore that she had a right to be the co-owner of the patent and its international extensions which protect the device for the intraocular transfer of active substances by iontophoresis.

By this agreement, Licensor of France renounces her right to take action against the Licensee of the Netherlands for recovery of the registered patents.

License Property
Licensor played a decisive role in development work on the applicator, a major part of the device.

Certain patents with respect to and which are used in Licensee's EGP-437 Combination Product.

US patent application N°09/225,206 (now granted, N° 6,154,671)

Field of Use
The licensed device is for the intraocular transfer of active substances by iontophoresis.
Iontophoresis is a process of transdermal drug delivery by use of a voltage gradient on the skin.

EGP-437 in clinical trials, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues though our proprietary innovative drug delivery system, the EyeGate® II Delivery System.

The EyeGate® II Delivery System and EGP-437, are designed to address two major issues in ophthalmic medicine lack of patient compliance and safety. The EyeGate® II Delivery System features a compact, elegant, and easy-to-use device that we believe has the potential to deliver drugs non-invasively and quickly into the ocular tissues through the use of iontophoresis, which can accelerate the onset of action, dramatically reduce treatment frequency versus eye drops and sustain therapeutic effect. Iontophoresis employs the use of a low electrical current that promotes the migration of a charged drug substance across biological membranes.

IPSCIO Record ID: 329732

License Grant
Licensor grants an exclusive right and license under the ANDA and the Technical Information to develop, manufacture and supply the Products pursuant to Licensee’s obligations under this Agreement, and an exclusive right to commercialize the Products outside the Territory.

The Parties shall undertake a Development Program with the Overall objective of obtaining all FDA approvals necessary for the commercialization of the Product.

Each party shall be the sole owner of the Technical Information of which only its employees and third party contractors arc inventors during the term of this Agreement. the Parties will jointly own the Technical Information of which both parties employees or contractors are joint inventors during the term of this agreement.

This agreement contains grants and grants back, exclusive and non-exclusive between the paries.

License Property
Listed Patents shall mean any and all United States Patents listed in Approved Drug Products with Therapeutic Equivalence Evaluation covering the Product or its Active Drug Substance in any of its forms.

Product shall mean an oxybutynin patch, the AB-rated generic equivalent of Oxytrol®.

Field of Use
Oxybutynin topical gel (OTG) is a transdermal delivery system for oxybutynin that has been approved by the United States Food and Drug Administration (FDA) based on results of a double-blind, placebo-controlled, phase 3 study in patients with OAB-associated incontinence.
Oxybutynin transdermal patches are used to treat an overactive bladder (a condition in which the bladder muscles contract uncontrollably and cause frequent urination, urgent need to urinate, and inability to control urination). Oxybutynin is in a class of medications called antimuscarinics. It works by relaxing the bladder muscles.

Licensee is in the business of developing and manufacturing pharmaceutical products  Licensee is a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products including transdermal and transmucosal delivery systems.

IPSCIO Record ID: 145984

License Grant
The Italian Licensee entered into an exclusive license agreement for the Licensors 7-day Estradiol patch for Italy, the Vatican and San Marino (the Territories).
License Property
The 7-day Estradiol patch is a product for the delivery of drug compounds through skin and mucosa.  Estradiol transdermal skin patches are used to treat certain symptoms of menopause.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 26398

License Grant
The Company has been granted of exclusive licensing and marketing rights to TheraTech, ownership of patents by the University; drug delivery research and development programs, controlled release drug delivery products which administer drugs through the skin, by oral delivery.

IPSCIO Record ID: 6128

License Grant
The Company entered into a development agreement to develop a Huperzine A Transdermal Delivery System.
License Property
This invention relates to a novel transdermal drug delivery system whereby Huperzine A (Hup A), a naturally occurred Acetylcholine esterase inhibitor traditionally used to alleviate memory problem, is formulated for transdermal administration suitable for the treatment of Alzheimer's Disease (AD) to increase the efficacy and convenience for outpatient care of AD patients. A controlled-release skin patch designed for once-a-week application of Hup A is provided for easy AD medication according to the invention.

IPSCIO Record ID: 5413

License Grant
The University hereby grants an exclusive right and license to Patented Ultrasound Enhancement of Transdermal Drug Delivery and Electric Field And Ultrasound For Transdermal Drug Delivery and Enhanced Antimicrobial Activity By Ultrasound for Dental Decay and Periodontal Disease Prevention and Treatment.
License Property
Patent No. 4,767,402, Issued August 30, 1988 “Ultrasound Enhancement of Transdermal Drug Delivery”

Patent No. 4,948,587, August 14, 1990 “Ultrasound Enhancement of Transbuccal Drug Delivery”

Patent No. 4,780,212, Issued October 25, 1988 “Ultrasound Enhancement of Membrane Permeability”

Patent No. 4,948,587, August 14, 1990 “Ultrasound Enhancement of Transbuccal Drug Delivery”

U.S.S.N. 08/507,060, Filed July 25, 1995 “Transdermal Protein Delivery Using Low-Frequency Sonophoresis”

U.S.S.N. 08/511,583, Filed August 4, 1995

U.S.S.N. 08/545,236, Filed October 19, 1995 “Transdermal Protein Delivery or Measurement Using Low-Frequency Sonophoresis”

IPSCIO Record ID: 203450

License Grant
Licensor grants an exclusive license in the Territory, and, the right to grant sub licenses, to rights under
(a) the Licensor Patents and Technology; and
(b) Licensors rights in any Joint Developments in the Field;
in each case to develop, use, make, have made, sell or otherwise dispose of the Products in the Field; provided, however, that notwithstanding the foregoing, Licensee shall not have the right to make or have made the Products other than as expressly contemplated by or provided in the Manufacturing and Supply Agreement, or to modify in any way the structure or composition of the Products, without the prior written consent of Licensor.
License Property
The patents cover the T-Patch and/or the TE Patch.

Products means the TE Patch and the T-Patch. For the avoidance of doubt, Products does not include Intrinsa.

The Once A Week T Patch means the transdermal patch drug delivery system to be developed by Licensor that will contain testosterone as the single active ingredient at a dosage in vitro of testosterone to be determined, that is intended to be worn for seven consecutive days, which shall be evidenced by either an NDA or a supplement to the NDA for the T Patch or lntrinsa.

The T-Patch means the transdermal patch drug delivery system developed by Licensor that contains testosterone as the single active ingredient at an in vivo dosage bio-equivalent to Intrinsa which is worn for three to four consecutive days, which shall be evidenced by either an NDA, a supplement thereto, or a supplement to the NDA, for Intrinsa, and shall include any minor improvements or modifications to such product that do not require additional development work.

The TE Patch means the transdermal patch drug delivery system to be developed by Licensor that will contain as the active ingredients a combination of testosterone and estrogen at a single dosage in vivo of testosterone to be determined, which dosage shall be in the range of about 50 to about 600 meg/day and which shall he evidenced by an NDA or a supplement thereto.

Field of Use
The Field means transdermal patches that contain testosterone ( or androgen derivatives of testosterone or androgens that convert to testosterone in the body) as the single active ingredient, and transdermal patches that contain the combination of testosterone (or androgen derivatives of testosterone or androgens that convert to testosterone in the body) plus estrogen or other related hormones (e.g. progestin), in each case at dosages of testosterone, androgen derivatives of testosterone or androgens that convert to testosterone in the body (in vivo) in the range of about 50 to about 600 meg/day, for use by women for any indication.

IPSCIO Record ID: 4876

License Grant
The Company grants an exclusive license for the transdermal delivery of high molecular weight drugs and other natural and synthetic materials.
License Property
Technologies relate to transdermal delivery of high molecular weight drugs and other natural and synthetic materials.

IPSCIO Record ID: 367578

License Grant
Israeli Licensor hereby grants to the Licensee an exclusive worldwide through multiple tier license, in the Territory, to 1) the Intellectual Property Rights resulting from and/or arising under the Development Plan and/or Development Results including Resulting Patents, and/or the Drug Formulation and/or Product ; and 2) to make, have made, use, have used and/or license the Drug Formulation and/or the Development Results, and 3) to make, have made, sell, have sold, use, have used, license, and/or import Product; and 4) an exclusive license in the Territory to any Patents covering the Drug Formulation and Product to enable the Licensee to make, have made, sell, have sold, and/or use Products. The Licensee shall not use the Drug Formulation and/or the Development Results for any purpose other than exercise of the License. Licensor hereby grants to the Licensee a non-exclusive license, in the Territory under the Licensor Patents, to use the Licensor Formulation Technology to 1) develop, make, have made, and use, the Drug Formulation, and 2) develop, make, have made, sell, have sold, and use, Product.
License Property
Licensor Patents shall mean the patents and/or patent applications covering or disclosing Licensor Formulation Technology; and including but not limited to,  U.S. Patent No. 5,540,934, U.S. Patent No. 5,716,638 and PCT International Application No. PCT/EP95/02397 and any continuations, continuations-in-part, extensions, divisions, substitutions or additions to such applications and all patents which are reissues thereof, re-validations and registrations based thereon, and any and all foreign patents and patent applications corresponding thereto.

5,540,934 – Compositions for applying active substances to or through the skin
5,716,638 – Composition for applying active substances to or through the skin

Product means a pharmaceutical preparation or composition containing the Drug Formulation which is covered by a Valid Patent Claim.

Drug means the Licensees organoselenium drug or materials, as specified in this Agreement, and its racemate, metabolite, derivatives, isomers, polymorphs, crystals.

Drug Formulation means the formulation of the Drug utilizing Licensors Formulation Technology.

Field of Use
Field of use is for Ethosome, a non-invasive, transdermal drug delivery technology.

Ethosomes are phospholipid nanovesicles used for dermal and transdermal delivery of molecules.

IPSCIO Record ID: 260368

License Grant
Licensor grants
—  an exclusive license, even as to Licensor, under the Licensed Patents to make, have made, import, use, sell, offer for sale and have sold Products in the Field in the Territory, subject to rights already granted to a Third Party under the Development Agreement between Licensor and and the Third Party; and,
—  a non-exclusive royalty-free license under the Future Licensor Patents to make, have made, import, use, sell, offer for sale and have sold Products in the Field in the Territory.

Licensor will assign to Licensee the Trademarks.

License Property
The inventions and know-how are regarding transdermal drug delivery systems and technologies.

The Trademark means the trademark applications and registrations for the mark MACROFLUX.

Microprojection System means a microprojection array having a plurality of microprojections which pierce at least through the outmost layer, i.e., the stratum comeum layer, of the skin.

Macroflux® transdermal microprojection delivery system provides unique benefits including convenient needle-free administration with room temperature stability for various therapeutic peptides, proteins, small molecules and vaccines.

skin patch technology provides rapid and reproducible intracutaneous administration of dry-coated antigen. The depth of skin penetration targets skin immune cells; the quantity of antigen delivered can be controlled by formulation, patch wearing time, and system size. This novel needle-free patch technology may ultimately have broad applications for a wide variety of therapeutic vaccines to improve efficacy and convenience of use.

Field of Use
The Field means passive, diffusion-mediated delivery of one or more therapeutic or prophylactic agents into or through the skin from a Microprojection System, which Microprojection System is coated with such therapeutic or prophylactic agents; or (b) diffusionmediated delivery of one or more therapeutic or prophylactic agents into or through the skin by way of pathways formed by a Microprojection System.

IPSCIO Record ID: 1724

License Grant
The Company entered into a second exclusive, worldwide, royalty bearing license agreement with the University for two patents, the rights to which are jointly held by the Licensor and Cellegy, for Drug Delivery By Skin Barrier Disruption.
License Property
This technology selectively modulates the skin’s barrier, with the goals of opening the skin barrier wider and keeping it open for a longer period of time (which may allow for the transdermal and topical delivery of larger and/or water soluble therapeutic, nutritional and cosmetic molecules), and reducing the potential for inducing skin inflammation, which sometimes accompanies use of certain traditional drug delivery technologies.
Field of Use
The rights granted apply to skin's barrier.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.